N-0385   Click here for help

GtoPdb Ligand ID: 11956

Synonyms: example 2 [WO2018112648A1] | Ms-QFR-Kbt | N0385
Compound class: Peptide or derivative
Comment: In March 2022, N-0385 was reported as a TMPRSS2 inhibitor, that has potential to disrupt infection of human host cells by coronaviruses by blocking TMPRSS2-mediated cleavage of the viral spike glycoprotein [3]. Mechanistically N-0385 operates as an 'entry inhibitor'. It is speculated that this type of inhibitor could offer prophylactic and therapeutic value across a broad range of coronaviruses (pan-coronavirus antiviral) and it appears to retain activity across SARS-CoV-2 variants. Structurally, N-0385 is a modified tripeptide. This chemical structure was claimed in pre-SARS-CoV-2 patents from Neomed Institute as a matriptase inhibitor (e.g. WO2018112648A1 [1] and US2019337981A1 [2]). The patents claim use for treatment or prevention of human coronavirus infections including hCoV-NL63, hCoV-OC43, hCoV-229E, hCoV-HKUI, SARS-CoV (Severe Acute Respiratory Syndrome-Corona Virus), or MERS-CoV (Middle East Respiratory Syndrome virus), in addition for potential to prevent infection by other types of viruses such as human parainfluenza viruses, and further therapeutic applications for hyperproliferative, respiratory and inflammatory disorders.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES NC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)c1nc2c(s1)cccc2)CCCN=C(N)N)Cc1ccccc1)NS(=O)(=O)C
Isomeric SMILES CS(=O)(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)c1nc2ccccc2s1
InChI InChI=1S/C28H36N8O6S2/c1-44(41,42)36-20(13-14-23(29)37)25(39)34-21(16-17-8-3-2-4-9-17)26(40)33-19(11-7-15-32-28(30)31)24(38)27-35-18-10-5-6-12-22(18)43-27/h2-6,8-10,12,19-21,36H,7,11,13-16H2,1H3,(H2,29,37)(H,33,40)(H,34,39)(H4,30,31,32)/t19-,20-,21-/m0/s1
InChI Key JTHVOFMYRRNGPA-ACRUOGEOSA-N
References
1. Boudreault P-L, Colombo E, Leduc R, Marsault E, Plancq B, Richter M. (2018)
Matriptase inhibitors and uses thereof.
Patent number: WO2018112648A1. Assignee: Neomed Institute. Priority date: 23/12/2016. Publication date: 28/06/2018.
2. Boudreault P-L, Colombo E, Leduc R, Marsault E, Plancq B, Richter M. (2019)
Matriptase inhibitors and uses thereof.
Patent number: US2019337981A1. Assignee: Neomed Institute. Priority date: 23/12/2016. Publication date: 07/11/2019.
3. Shapira T, Monreal IA, Dion SP, Buchholz DW, Imbiakha B, Olmstead AD, Jager M, Désilets A, Gao G, Martins M et al.. (2022)
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Nature, 605 (7909): 340-348. [PMID:35344983]